Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205778410> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W3205778410 endingPage "1711" @default.
- W3205778410 startingPage "1711" @default.
- W3205778410 abstract "Cancer, which can invade almost all parts of the body, accounts for 18% of all deaths throughout the world and ranks as one of the leading causes of death among non-communicable diseases [1, 2]. Since cancers have a high chance of curing if appropriate treatment is provided, anticancer agents are critical for tumor therapy. However, the continuous emergency of drug-resistant cancer has already become one of the major challenges in the control and eradication of cancers [3, 4]. Therefore, dis-covering the next wave of anticancer agents with high potency against drug-resistant forms is vital. Coumarin, podophyllotoxin, hydroxamic acid, ferrocene, and acridine derivatives cannot only in-hibit tumor proliferation, invasion, and metastasis by acting on multiple intracellular signaling net-work molecules but also have reverse cancer multidrug resistance effect [5-9]. Moreover, many cur-rent available anticancer agents own these pharmacophores, demonstrating the potential of these pharmacophores to fight against various cancers, including drug-resistant forms. Hybridization repre-sents a promising strategy to develop novel anticancer agents since hybrid molecules can simultaneously act on dual or multi-ple cancer-relevant targets, such as metalloproteinases, ATP binding cassette subfamily G member 2 (ABCG2), human mito-chondrial peptide deformylase, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), P-glycoprotein (P-gp), tubulin, and vascular endothelial growth factor (VEGF) [10, 11]. Thus, hybrid molecules can increase specificity, reduce side effects, improve patient compliance, and overcome drug resistance [12]. Accordingly, a combination of coumarin, podophyl-lotoxin, hydroxamic acid, ferrocene, or acridine with other anticancer pharmacophores is an attractive strategy for the discov-ery of novel anticancer agents with potent activity against various cancers, especially drug-resistant forms. This special issue focuses on the current scenario of coumarin, podophyllotoxin, hydroxamic acid, ferrocene, and acridine hybrids with in vitro and in vivo anticancer potential. The mechanisms of action, the critical aspects of design, and structure-activity relationships are also discussed to pave the way for the further rational design of novel candidates with excellent effi-ciency against drug-resistant cancers." @default.
- W3205778410 created "2021-10-25" @default.
- W3205778410 creator A5072815084 @default.
- W3205778410 date "2021-07-01" @default.
- W3205778410 modified "2023-09-23" @default.
- W3205778410 title "Hybrid Molecules with Potential Activity against Drug-resistant Cancer – PART-I" @default.
- W3205778410 doi "https://doi.org/10.2174/156802662119211011143248" @default.
- W3205778410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34726134" @default.
- W3205778410 hasPublicationYear "2021" @default.
- W3205778410 type Work @default.
- W3205778410 sameAs 3205778410 @default.
- W3205778410 citedByCount "0" @default.
- W3205778410 crossrefType "journal-article" @default.
- W3205778410 hasAuthorship W3205778410A5072815084 @default.
- W3205778410 hasConcept C114851261 @default.
- W3205778410 hasConcept C121608353 @default.
- W3205778410 hasConcept C133936738 @default.
- W3205778410 hasConcept C185592680 @default.
- W3205778410 hasConcept C2780035454 @default.
- W3205778410 hasConcept C502942594 @default.
- W3205778410 hasConcept C54355233 @default.
- W3205778410 hasConcept C55493867 @default.
- W3205778410 hasConcept C56173144 @default.
- W3205778410 hasConcept C86803240 @default.
- W3205778410 hasConcept C89423630 @default.
- W3205778410 hasConcept C96232424 @default.
- W3205778410 hasConcept C98274493 @default.
- W3205778410 hasConceptScore W3205778410C114851261 @default.
- W3205778410 hasConceptScore W3205778410C121608353 @default.
- W3205778410 hasConceptScore W3205778410C133936738 @default.
- W3205778410 hasConceptScore W3205778410C185592680 @default.
- W3205778410 hasConceptScore W3205778410C2780035454 @default.
- W3205778410 hasConceptScore W3205778410C502942594 @default.
- W3205778410 hasConceptScore W3205778410C54355233 @default.
- W3205778410 hasConceptScore W3205778410C55493867 @default.
- W3205778410 hasConceptScore W3205778410C56173144 @default.
- W3205778410 hasConceptScore W3205778410C86803240 @default.
- W3205778410 hasConceptScore W3205778410C89423630 @default.
- W3205778410 hasConceptScore W3205778410C96232424 @default.
- W3205778410 hasConceptScore W3205778410C98274493 @default.
- W3205778410 hasIssue "19" @default.
- W3205778410 hasLocation W32057784101 @default.
- W3205778410 hasLocation W32057784102 @default.
- W3205778410 hasOpenAccess W3205778410 @default.
- W3205778410 hasPrimaryLocation W32057784101 @default.
- W3205778410 hasRelatedWork W1388953 @default.
- W3205778410 hasRelatedWork W1594398 @default.
- W3205778410 hasRelatedWork W23247929 @default.
- W3205778410 hasRelatedWork W26453273 @default.
- W3205778410 hasRelatedWork W27077640 @default.
- W3205778410 hasRelatedWork W27810895 @default.
- W3205778410 hasRelatedWork W30632665 @default.
- W3205778410 hasRelatedWork W8302687 @default.
- W3205778410 hasRelatedWork W8698494 @default.
- W3205778410 hasRelatedWork W8753426 @default.
- W3205778410 hasVolume "21" @default.
- W3205778410 isParatext "false" @default.
- W3205778410 isRetracted "false" @default.
- W3205778410 magId "3205778410" @default.
- W3205778410 workType "article" @default.